BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1219 related articles for article (PubMed ID: 29449189)

  • 21. Sequential Chemoradiotherapy Compared to Radiotherapy in Endometrial Carcinoma.
    Elemam O; Abdelkhalek S; Abdelmoety D; Aboelnaga E; Baraka R; Zeeneldine A
    Asian Pac J Cancer Prev; 2020 May; 21(5):1327-1332. PubMed ID: 32458640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
    Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of adjuvant therapy in stage IIIC2 endometrial cancer.
    Bogani G; Cappuccio S; Casarin J; Narasimhulu DMM; Cilby WA; Glaser GE; Weaver AL; McGree ME; Keeney GL; Weroha J; Petersen IA; Mariani A
    Int J Gynecol Cancer; 2020 Aug; 30(8):1169-1176. PubMed ID: 32646864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
    Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Gallardo-Rincon D; Blagden S; Brenton J; Perren TJ; Sundar S; Lord R; Dark G; Hall M; Banerjee S; Glasspool RM; Hanna CL; Williams S; Scatchard KM; Nam H; Essapen S; Parkinson C; McAvan L; Swart AM; Popoola B; Schiavone F; Badrock J; Fananapazir F; Cook AD; Parmar M; Kaplan R; Ledermann JA
    Lancet Oncol; 2022 Jul; 23(7):919-930. PubMed ID: 35690073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer.
    Montes de Oca MK; Albright BB; Secord AA; Havrilesky LJ; Moss HA
    Int J Gynecol Cancer; 2021 Dec; 31(12):1549-1556. PubMed ID: 34725205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
    Roach M; Moughan J; Lawton CAF; Dicker AP; Zeitzer KL; Gore EM; Kwok Y; Seider MJ; Hsu IC; Hartford AC; Horwitz EM; Yamoah K; Jones CU; Michalski JM; Lee WR; Pisansky TM; Rabinovitch R; Rotman M; Pryzant RM; Kim HE; Thomas CR; Shipley WU; Sandler HM
    Lancet Oncol; 2018 Nov; 19(11):1504-1515. PubMed ID: 30316827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma.
    Creutzberg CL; van Putten WL; Koper PC; Lybeert ML; Jobsen JJ; Wárlám-Rodenhuis CC; De Winter KA; Lutgens LC; van den Bergh AC; van de Steen-Banasik E; Beerman H; van Lent M
    Lancet; 2000 Apr; 355(9213):1404-11. PubMed ID: 10791524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
    Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
    Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Liu LT; Liu H; Huang Y; Yang JH; Xie SY; Li YY; Guo SS; Qi B; Li XY; Chen DP; Jin F; Sun XS; Yang ZC; Liu SL; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Qiu F; Yang Q; Liang YJ; Jia GD; Wen DX; Yan JJ; Zhao C; Chen QY; Sun R; Tang LQ; Mai HQ
    Lancet Oncol; 2023 Jul; 24(7):798-810. PubMed ID: 37290468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
    Conroy T; Galais MP; Raoul JL; Bouché O; Gourgou-Bourgade S; Douillard JY; Etienne PL; Boige V; Martel-Lafay I; Michel P; Llacer-Moscardo C; François E; Créhange G; Abdelghani MB; Juzyna B; Bedenne L; Adenis A;
    Lancet Oncol; 2014 Mar; 15(3):305-14. PubMed ID: 24556041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
    Earl HM; Hiller L; Howard HC; Dunn JA; Young J; Bowden SJ; McDermaid M; Waterhouse AK; Wilson G; Agrawal R; O'Reilly S; Bowman A; Ritchie DM; Goodman A; Hickish T; McAdam K; Cameron D; Dodwell D; Rea DW; Caldas C; Provenzano E; Abraham JE; Canney P; Crown JP; Kennedy MJ; Coleman R; Leonard RC; Carmichael JA; Wardley AM; Poole CJ;
    Lancet Oncol; 2017 Jun; 18(6):755-769. PubMed ID: 28479233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy.
    Reshko LB; Gaskins JT; Dryden SM; Metzinger DS; Todd SL; Eldredge-Hindy HB; Silva SR
    Int J Gynecol Cancer; 2021 May; 31(5):694-701. PubMed ID: 33741653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma.
    Xu MJ; Chu C; Rubin S; Lin LL
    Am J Clin Oncol; 2017 Dec; 40(6):598-604. PubMed ID: 26237194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
    Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
    Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 61.